New FARAWAVE™ NAV Ablation Catheter and
FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide
visualization during pulsed field ablation
MARLBOROUGH, Mass., Oct. 18,
2024 /PRNewswire/ -- Boston Scientific Corporation
(NYSE: BSX) today announced it has received U.S. Food and Drug
Administration (FDA) approval for the navigation-enabled FARAWAVE™
NAV Ablation Catheter for the treatment of paroxysmal atrial
fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW™
Software, which will combine to provide visualization for cardiac
ablation procedures with the FARAPULSE™ Pulsed Field Ablation (PFA)
System. These technologies are compatible exclusively with Boston
Scientific's existing cardiac mapping technology and the company's
latest offering, the OPAL HDx™ Mapping System.
Today, physicians may utilize a separate mapping catheter prior
to a cardiac PFA procedure to examine and analyze the heart's
electrical patterns and plan the therapeutic applications for each
patient. The FARAWAVE NAV Ablation Catheter builds upon the current
FARAWAVE catheter by adding magnetic navigation capabilities,
enabling cardiac mapping and PFA therapy delivery within a single
integrated catheter, while minimizing the need for additional
device exchanges. Mapped procedures with the FARAPULSE PFA System
are visually depicted for physicians via the FARAVIEW Software,
which offers a dynamic view of catheter placement, shape and
rotation.
"The addition of the FARAWAVE NAV Ablation Catheter and FARAVIEW
Software to our portfolio provides a next-level pulsed field
ablation mapping experience with cost-effective tools developed
specifically and uniquely for the FARAPULSE PFA System," said
Nick Spadea-Anello, president,
Electrophysiology, Boston Scientific. "Built on this safe and
clinically-proven platform – which has been used to treat more than
125,000 patients globally – the visualization capabilities offered
by these new technologies are designed to increase confidence in
therapy delivery and simplify mapped workflows during PFA
procedures."
The latest advancement within the Boston Scientific PFA
portfolio, the FARAVIEW Software magnetically tracks the FARAWAVE
NAV Ablation Catheter, which allows physicians to see where pulsed
fields have been applied and visualize cumulative therapy delivery
to guide ablation strategy. Delivery of PFA with the FARAWAVE NAV
Ablation Catheter can be tracked through automated tagging
technology, which is intended to assist physicians in planning,
executing and confirming application of therapy by showing the
approximate pulsed field locations within the heart, based on the
catheter's position.
"In clinical use, the FARAVIEW Software and FARAWAVE NAV
Ablation Catheter produced detailed cardiac maps that could improve
guidance, limit fluoroscopy times and assist physicians in
assessing the location of energy delivered during PFA procedures,"
said Vivek Reddy, M.D., director of
electrophysiology, Mount Sinai Fuster Heart Hospital, New York. "The addition of navigation and
visualization capabilities to the FARAPULSE PFA System could aid
workflow efficiency and enhance the treatment physicians can
provide to patients living with AF."
Boston Scientific will immediately launch the FARAWAVE NAV
Ablation Catheter and FARAVIEW Software in the U.S. More
information is available here.
*Dr. Vivek Reddy is a paid consultant of Boston
Scientific Corporation. He has not been compensated in connection
with this press release.
About Boston Scientific
Boston Scientific transforms lives through innovative medical
technologies that improve the health of patients around the world.
As a global medical technology leader for more than 45 years, we
advance science for life by providing a broad range of
high-performance solutions that address unmet patient needs and
reduce the cost of healthcare. Our portfolio of devices and
therapies helps physicians diagnose and treat complex
cardiovascular, respiratory, digestive, oncological, neurological
and urological diseases and conditions. Learn more at
www.bostonscientific.com and connect
on LinkedIn and X, formerly Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements
are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be
guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding our business plans and product performance and impact,
and new and anticipated product approvals and launches. If
our underlying assumptions turn out to be incorrect, or if certain
risks or uncertainties materialize, actual results could vary
materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in
some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; manufacturing, distribution and supply chain
disruptions and cost increases; variations in outcomes of ongoing
and future clinical trials and market studies; new product
introductions; demographic trends; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these
factors are difficult or impossible to predict accurately and many
of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A
– Risk Factors in our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, which
we may update in Part II, Item 1A – Risk
Factors in Quarterly Reports on Form 10-Q we have filed or
will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements, except as required by
law. This cautionary statement is applicable to all
forward-looking statements contained in this document.
CONTACTS:
Steve Bailey
Media Relations
(651) 582-4343 (office)
Steve.Bailey@bsci.com
Jon Monson
Investor Relations
(508) 683-5450
BSXInvestorRelations@bsci.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/boston-scientific-launches-next-generation-of-cardiac-mapping-for-the-farapulse-pulsed-field-ablation-system-302280503.html
SOURCE Boston Scientific Corporation
